[Translation] A randomized, controlled, open-label, multicenter pivotal confirmatory phase III clinical study on the efficacy and safety of APG-2575 (Lisaftoclax) combined with acotinib versus immunochemotherapy in the treatment of newly diagnosed chronic lymphocytic leukemia/small lymphocytic lymphoma
比较APG-2575联合阿可替尼对比免疫化疗(FCR或R-Clb)在初治CLL/SLL患者的疗效和安全性。
[Translation] To compare the efficacy and safety of APG-2575 combined with acotinib versus immunochemotherapy (FCR or R-Clb) in patients with newly diagnosed CLL/SLL.